Investigation of the effective and safe use of the drug product in the treatment of actinic keratosis on extremities and trunk/neck.

Registry ID

EUCTR2017-000486-72

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Biofrontera Bioscience GmbH

Start date

2017-07-28

Last update

2026-08-16

Conditions

• Actinic keratosis (AK)

Summary

Primary objective: To compare the efficacy of BF-200 ALA (also referred to as Ameluz®) with placebo for treatment of mild to severe actinic keratosis (AK) located on extremities and trunk/ neck with PDT when using the BF RhodoLED® lamp.

Locations

• , , Germany

View on source registry